Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors
about
An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis.Aberrant regulation of Wnt signaling in hepatocellular carcinomaModeling progressive non-alcoholic fatty liver disease in the laboratory mouse.c-Myc and transforming growth factor α enhance the development of hepatic lesions due to mutant β-catenin in transgenic miceFAK is required for c-Met/β-catenin-driven hepatocarcinogenesis.SKP2 cooperates with N-Ras or AKT to induce liver tumor development in mice.Stem cells in liver diseases and cancer: recent advances on the path to new therapies.Defining the critical hurdles in cancer immunotherapy.A multi-mineral natural product inhibits liver tumor formation in C57BL/6 mice.Chronic inflammation, immune escape, and oncogenesis in the liver: a unique neighborhood for novel intersections.Serum-based tracking of de novo initiated liver cancer progression reveals early immunoregulation and response to therapy.Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells.Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotypeLTβR signalling preferentially accelerates oncogenic AKT-initiated liver tumoursPharmacological modulation of beta-catenin and its applications in cancer therapyInflammation and liver tumorigenesis.Hydrodynamic transfection for generation of novel mouse models for liver cancer research.Current concepts of immune based treatments for patients with HCC: from basic science to novel treatment approaches.Transgenic mouse models generated by hydrodynamic transfection for genetic studies of liver cancer and preclinical testing of anti-cancer therapy.Delivery strategies and potential targets for siRNA in major cancer typesβ-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma.FAK Kinase Activity Is Required for the Progression of c-MET/β-Catenin-Driven Hepataocellular Carcinoma.Nanoparticle-formulated siRNA targeting integrins inhibits hepatocellular carcinoma progression in mice.FOXO3, estrogen receptor alpha, and androgen receptor impact tumor growth rate and infiltration of dendritic cell subsets differentially between male and female mice.Oncogenic dependency on β-catenin in liver cancer cell lines correlates with pathway activation.Prognostic significance of c-Met, β-catenin and FAK in patients with hepatocellular carcinoma following surgery.Protein disulfide isomerase a4 acts as a novel regulator of cancer growth through the procaspase pathway.Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
P2860
Q27310334-BFCA1BF6-B8B3-48AC-B2C6-E0C0F8D1AF59Q28079789-1DE9E07D-C3AF-42DF-A1F8-7B0B4056911DQ34185231-A7F9A137-EE80-4383-B727-915ED363D5AEQ34539365-BDE9062E-78FB-472B-92C2-10CBAC9F2F20Q34791002-E19D14EC-ECDA-41F1-9440-D074211F2D78Q35273519-BD64B655-510C-4197-87B0-27609275E64DQ35631841-2929E1CD-4FEA-4100-9570-D55579FB15ACQ35916968-D38A77EF-0416-4DBE-A336-2D80870553B1Q35990259-9D0E9FD1-B345-464C-AF36-890B2C0F4E18Q36055039-215BC5CF-9698-43CE-8AF0-E4D5DC5EF657Q36190850-A806D405-9B35-4B4E-9D06-31AA56C68DCDQ36415111-8FE1A815-5C64-49D2-BEDB-31319675E165Q36922108-FE37F93F-14CC-4621-84ED-939540EFAE1AQ37282535-1E3BC32F-E3A7-4E60-A0B4-CDD38E2741DBQ38089341-22FD0665-54D0-47B9-90D3-00BE7E9F2DADQ38107461-3E596483-4A05-45DF-A9F1-7F4DE5EA6BA6Q38183539-4037CEDC-B872-4836-A7B4-55191F7F3FA2Q38349665-A407CAD4-C253-4B5F-8588-CA7B6538A1D9Q38556534-B71C48BB-D846-4AA9-8459-762B38516E5AQ38853191-5E854E83-099D-4165-8CEE-CB7DDA675CFAQ38993024-EEFB5A34-1280-4E9B-8F86-72088009543AQ41466023-F5038734-582D-4563-AED0-624622C63585Q41847265-64E55992-FE50-45CC-8F02-D2F4FC0C7770Q47850258-779435E7-2ACD-496A-A1CF-762CEB4CDAD4Q49165832-9F78ACB1-9AD2-49F9-8B9E-CFAFBF601DC3Q50284721-B06EA79B-C28C-4FDE-A216-6B7013C97E6AQ50986588-8F339895-14C7-40E9-9A22-F7D59F265564Q54976722-6B690570-D752-4E30-93DB-76F3C973B819
P2860
Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@ast
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@en
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@nl
type
label
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@ast
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@en
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@nl
prefLabel
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@ast
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@en
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@nl
P2093
P2860
P3181
P1433
P1476
Coactivation of AKT and β-cate ...... tion of lipogenic liver tumors
@en
P2093
Anthony J Scarzello
Jesper B Andersen
Jimmy K Stauffer
Jonathan M Weiss
Rachel L De Kluyver
Robert H Wiltrout
Snorri S Thorgeirsson
Timothy C Back
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-10-2705
P407
P577
2011-04-01T00:00:00Z